Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PH-139: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

NCT04827810 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT04827810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04827810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PH-139: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 1
Overall status
Suspended
Start date
November 5, 2021
Completion date
December 30, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, lymphoma